🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSurvodutide MASH Phase 2b — need advice Page 3

Survodutide MASH Phase 2b — need advice

FranDenver Thu, Mar 7, 2024 at 10:16 PM 16 replies 2,044 viewsPage 3 of 4
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Mar 14, 2024 at 6:14 PM#11
EndoResFellow said:
The liver data is among the strongest non-weight findings in the class.

This answered a question I did not know how to ask.

4 2tane_welly, Dr.PathRoch, mona_PHX and 1 other
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Mar 17, 2024 at 6:28 AM#12

Clinical perspective, offered as context rather than as advice. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

Happy to go further on any of that.

5 3Dr.SurgeonPGH, rachel_ABQ, traveltech_sara and 2 others
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Mar 19, 2024 at 6:41 PM#13
PharmHunterJen said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Mar 19, 2024 at 7:41 PM
6 4Dr.EndoEP, GraceAZ_72, carl_compliance and 3 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Mar 22, 2024 at 6:52 AM#14

Adding the numbers, since they settle part of this. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

Last edited: Mar 22, 2024 at 10:52 AM
7 5FranDenver, Dr.BariatricHTX, LindaRN_retired and 4 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Mar 24, 2024 at 7:02 PM#15

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Tagging this one for the weekly digest.

8 6PurityPaulOR, MaxMetOK, MounjBrad and 5 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register